145 related articles for article (PubMed ID: 30300823)
21. [The Mechanism of Combination using mTORC1/2 Inhibitor and Imatinib to Suppress Cell Proliferation of Ph
Wu JH; Shi FF; Gong YP; Shi R
Sichuan Da Xue Xue Bao Yi Xue Ban; 2017 Mar; 48(2):216-220. PubMed ID: 28612529
[TBL] [Abstract][Full Text] [Related]
22. Dual inhibition of the mTORC1 and mTORC2 signaling pathways is a promising therapeutic target for adult T-cell leukemia.
Kawata T; Tada K; Kobayashi M; Sakamoto T; Takiuchi Y; Iwai F; Sakurada M; Hishizawa M; Shirakawa K; Shindo K; Sato H; Takaori-Kondo A
Cancer Sci; 2018 Jan; 109(1):103-111. PubMed ID: 29077243
[TBL] [Abstract][Full Text] [Related]
23. An mTOR kinase inhibitor slows disease progression in a rat model of polycystic kidney disease.
Ravichandran K; Zafar I; Ozkok A; Edelstein CL
Nephrol Dial Transplant; 2015 Jan; 30(1):45-53. PubMed ID: 25239638
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of JNK-mediated autophagy enhances NSCLC cell sensitivity to mTORC1/2 inhibitors.
Jin HO; Hong SE; Park JA; Chang YH; Hong YJ; Park IC; Lee JK
Sci Rep; 2016 Jun; 6():28945. PubMed ID: 27358039
[TBL] [Abstract][Full Text] [Related]
25. A novel AML-selective TRAIL fusion protein that is superior to Gemtuzumab Ozogamicin in terms of in vitro selectivity, activity and stability.
ten Cate B; Bremer E; de Bruyn M; Bijma T; Samplonius D; Schwemmlein M; Huls G; Fey G; Helfrich W
Leukemia; 2009 Aug; 23(8):1389-97. PubMed ID: 19262596
[TBL] [Abstract][Full Text] [Related]
26. The peripheral benzodiazepine receptor ligand PK11195 overcomes different resistance mechanisms to sensitize AML cells to gemtuzumab ozogamicin.
Walter RB; Raden BW; Cronk MR; Bernstein ID; Appelbaum FR; Banker DE
Blood; 2004 Jun; 103(11):4276-84. PubMed ID: 14962898
[TBL] [Abstract][Full Text] [Related]
27. Deficient activation of Bak and Bax confers resistance to gemtuzumab ozogamicin-induced apoptotic cell death in AML.
Haag P; Viktorsson K; Lindberg ML; Kanter L; Lewensohn R; Stenke L
Exp Hematol; 2009 Jun; 37(6):755-66. PubMed ID: 19463775
[TBL] [Abstract][Full Text] [Related]
28. Induction of DNA strand breaks is critical to predict the cytotoxicity of gemtuzumab ozogamicin against leukemic cells.
Yamauchi T; Matsuda Y; Tasaki T; Negoro E; Ikegaya S; Takagi K; Yoshida A; Urasaki Y; Ueda T
Cancer Sci; 2012 Sep; 103(9):1722-9. PubMed ID: 22632031
[TBL] [Abstract][Full Text] [Related]
29. HSP70 Acetylation Prevents Combined mTORC1/2 Inhibitor and Curcumin Treatment-Induced Apoptosis.
Seo SU; Min KJ; Woo SM; Seo JH; Kwon TK
Molecules; 2018 Oct; 23(11):. PubMed ID: 30356017
[TBL] [Abstract][Full Text] [Related]
30. Gemtuzumab Ozogamicin (GO) Inclusion to Induction Chemotherapy Eliminates Leukemic Initiating Cells and Significantly Improves Survival in Mouse Models of Acute Myeloid Leukemia.
Zhang CC; Yan Z; Pascual B; Jackson-Fisher A; Huang DS; Zong Q; Elliott M; Fan C; Huser N; Lee J; Sung M; Sapra P
Neoplasia; 2018 Jan; 20(1):1-11. PubMed ID: 29172076
[TBL] [Abstract][Full Text] [Related]
31. The histone deacetylase inhibitor valproic acid potently augments gemtuzumab ozogamicin-induced apoptosis in acute myeloid leukemic cells.
ten Cate B; Samplonius DF; Bijma T; de Leij LF; Helfrich W; Bremer E
Leukemia; 2007 Feb; 21(2):248-52. PubMed ID: 17122863
[TBL] [Abstract][Full Text] [Related]
32. 1,25-Dihydroxyvitamin D
Kim Y; Kim HS; Sohn J; Ji JD
Biochem Biophys Res Commun; 2019 Nov; 519(4):909-915. PubMed ID: 31563324
[TBL] [Abstract][Full Text] [Related]
33. ATP-site binding inhibitor effectively targets mTORC1 and mTORC2 complexes in glioblastoma.
Neil J; Shannon C; Mohan A; Laurent D; Murali R; Jhanwar-Uniyal M
Int J Oncol; 2016 Mar; 48(3):1045-52. PubMed ID: 26719046
[TBL] [Abstract][Full Text] [Related]
34. GSK3 inhibitor enhances gemtuzumab ozogamicin-induced apoptosis in primary human leukemia cells by overcoming multiple mechanisms of resistance.
Inase A; Maimaitili Y; Kimbara S; Mizutani Y; Miyata Y; Ohata S; Matsumoto H; Kitao A; Sakai R; Kawaguchi K; Higashime A; Nagao S; Kurata K; Goto H; Kawamoto S; Yakushijin K; Minami H; Matsuoka H
EJHaem; 2023 Feb; 4(1):153-164. PubMed ID: 36819180
[TBL] [Abstract][Full Text] [Related]
35. Discrete signaling mechanisms of mTORC1 and mTORC2: Connected yet apart in cellular and molecular aspects.
Jhanwar-Uniyal M; Amin AG; Cooper JB; Das K; Schmidt MH; Murali R
Adv Biol Regul; 2017 May; 64():39-48. PubMed ID: 28189457
[TBL] [Abstract][Full Text] [Related]
36. The biology of MDR1-P-glycoprotein (MDR1-Pgp) in designing functional antibody drug conjugates (ADCs): the experience of gemtuzumab ozogamicin.
Cianfriglia M
Ann Ist Super Sanita; 2013; 49(2):150-68. PubMed ID: 23771260
[TBL] [Abstract][Full Text] [Related]
37. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.
Bross PF; Beitz J; Chen G; Chen XH; Duffy E; Kieffer L; Roy S; Sridhara R; Rahman A; Williams G; Pazdur R
Clin Cancer Res; 2001 Jun; 7(6):1490-6. PubMed ID: 11410481
[TBL] [Abstract][Full Text] [Related]
38. Combined mTORC1/mTORC2 inhibition blocks growth and induces catastrophic macropinocytosis in cancer cells.
Srivastava RK; Li C; Khan J; Banerjee NS; Chow LT; Athar M
Proc Natl Acad Sci U S A; 2019 Dec; 116(49):24583-24592. PubMed ID: 31732667
[TBL] [Abstract][Full Text] [Related]
39. [Combination of PP242 and dasatinib suppresses the progression of acute myeloid leukemia in a mouse model].
Qu YH; Liu HT; He FC
Zhonghua Yi Xue Za Zhi; 2017 May; 97(20):1584-1588. PubMed ID: 28592067
[No Abstract] [Full Text] [Related]
40. CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance.
Linenberger ML
Leukemia; 2005 Feb; 19(2):176-82. PubMed ID: 15592433
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
